Quantum Leap Healthcare Collaborative

Agent Information

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
I-SPY Trial Manuscript
<- Back to All Agents


Trade Name:
Currently Enrolling
Agent Chaperone(s):
Treatment Protocol:
Tucatinib taken orally 300mg BID, paclitaxel administered at 80 mg/m2 weekly (q1w), and Trastuzumab at 4 mg/kg (loading dose) and 2 mg/kg (thereafter) weekly (q1w) for a total of 12 weeks. This regimen was followed by AC (q2w or q3w) for 4 weeks.
Date Entered I-SPY:
January 2, 2019
Date Left I-SPY:
No. Participants in Arm:
Graduating Subtypes:
Agent Description:

Tucatinib an orally bioavailable, small molecule tyrosine kinase inhibitor (TKI) that is highly selective for HER2, a growth factor receptor that is over-expressed in multiple cancers, including breast, colorectal, esophageal, gastric, lung and ovarian cancers. It is over-expressed in approximately 20% of breast cancers. It has shown efficacy and safety in nonclinical and clinical studies. Tucatinib may therefore be a beneficial therapeutic option for patients with solid malignancies including breast cancer that are associated with HER2 overexpression or mutation. As tucatinib in combination has shown early evidence of activity against brain metastases from HER2+ breast cancer, tucatinib also has the potential to benefit early-stage patients with occult micrometastatic disease in the brain.

Final pCR Probabilities:
Primary Manuscript:
abstractpdfdoi link